

Vincenza Conteduca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5708297/publications.pdf>

Version: 2024-02-01

130
papers

4,847
citations

87723

38
h-index

110170

64
g-index

134
all docs

134
docs citations

134
times ranked

6631
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. <i>Molecular Oncology</i> , 2022, 16, 538-548.	2.1	4
2	Plasma tumor <scp>DNA</scp> is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. <i>International Journal of Cancer</i> , 2022, 150, 1166-1173.	2.3	4
3	Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1545-1548.	2.0	4
4	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. <i>BMC Medicine</i> , 2022, 20, 48.	2.3	8
5	Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 928-938.	3.2	29
6	Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. <i>Cancers</i> , 2022, 14, 2219.	1.7	5
7	Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer. <i>Scientific Reports</i> , 2022, 12, 7319.	1.6	1
8	High exosomal PD-L1 expression in relation to lymph node progression in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (abi) or enzalutamide (enza).. <i>Journal of Clinical Oncology</i> , 2022, 40, e17038-e17038.	0.8	0
9	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. <i>European Urology</i> , 2021, 79, 722-733.	0.9	17
10	The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103199.	2.0	16
11	New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2021, 10, 193.	1.8	26
12	Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 524-531.	2.0	32
13	Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 740-744.	2.6	7
14	Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	1.4	19
15	Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Cancers</i> , 2021, 13, 840.	1.7	17
16	Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5145.	1.8	2
17	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021, 26, 740-750.	1.9	19
18	An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 631-640.	1.5	4

#	ARTICLE	IF	CITATIONS
19	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <i>Nature Communications</i> , 2021, 12, 3372.	5.8	45
20	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	2.9	13
21	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021, 152, 49-59.	1.3	4
22	Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 716467.	1.3	8
23	Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. <i>Npj Precision Oncology</i> , 2021, 5, 76.	2.3	25
24	Targeted radioactive therapy for prostate cancer. <i>Lancet, The</i> , 2021, 398, 487-488.	6.3	0
25	Talazoparib: a new biomarker-directed therapy in advanced prostate cancer. <i>Lancet Oncology, The</i> , 2021, 22, 1203-1204.	5.1	1
26	Epigenetics in prostate cancer: clinical implications. <i>Translational Andrology and Urology</i> , 2021, 10, 3104-3116.	0.6	4
27	Epigenetics in prostate cancer: clinical implications. <i>Translational Andrology and Urology</i> , 2021, 10, 3104-3116.	0.6	28
28	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. <i>European Urology Oncology</i> , 2020, 3, 176-182.	2.6	19
29	Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. <i>Frontiers in Oncology</i> , 2020, 10, 567809.	1.3	5
30	Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 565857.	1.3	14
31	Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 982-987.	2.9	22
32	Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2091-2099.	0.9	8
33	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. , 2020, 8, e001154.		13
34	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	2.8	70
35	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1157-1164.	1.9	44
36	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1950.	1.0	3

#	ARTICLE	IF	CITATIONS
37	A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103036.	2.0	5
38	Genome-wide plasma DNA methylation features of metastatic prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1991-2000.	3.9	68
39	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1653-1668.	3.9	122
40	Identification of single nucleotide variants using position-specific error estimation in deep sequencing data. <i>BMC Medical Genomics</i> , 2019, 12, 115.	0.7	10
41	Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>Prostate</i> , 2019, 79, 1211-1220.	1.2	17
42	Plasma Androgen Receptor in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1719.	1.7	13
43	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019, 17, 296.	1.8	13
44	Clinical features of neuroendocrine prostate cancer. <i>European Journal of Cancer</i> , 2019, 121, 7-18.	1.3	195
45	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	1.3	29
46	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	8
47	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	105
48	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2019, 15, 1115-1123.	1.1	9
49	Biological Evolution of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 147-154.	1.6	71
50	Psychosocial Issues in Long-Term Survivors of Testicular Cancer. <i>Frontiers in Endocrinology</i> , 2019, 10, 113.	1.5	39
51	The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. <i>Cancers</i> , 2019, 11, 1935.	1.7	21
52	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	15
53	Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 195-205.	2.0	39
54	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 368-373.	0.9	64

#	ARTICLE	IF	CITATIONS
55	Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.. Journal of Clinical Oncology, 2019, 37, 3020-3020.	0.8	3
56	Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.. Journal of Clinical Oncology, 2019, 37, 272-272.	0.8	8
57	Immunogenomic landscape of neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2019, 37, 224-224.	0.8	1
58	Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 240.e1-240.e11.	0.8	20
59	Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 461-467.	1.5	9
60	Prognostic value of 18Fâ€“choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 348-354.	3.3	22
61	Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680â€“7. European Urology, 2018, 73, e9-e10.	0.9	1
62	BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. JCO Precision Oncology, 2018, 2, 1-10.	1.5	4
63	Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. BMC Cancer, 2018, 18, 1267.	1.1	12
64	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Scientific Reports, 2018, 8, 15442.	1.6	21
65	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. Future Oncology, 2018, 14, 2691-2699.	1.1	3
66	Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol 2018;74:283â€“91. European Urology, 2018, 74, e67-e68.	0.9	2
67	Reply to the letter to the editor â€“Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancerâ€™ by Yang et al.. Annals of Oncology, 2018, 29, 1879-1880.	0.6	1
68	Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5074-5074.	0.8	2
69	AR Copy Number and AR Signaling-directed Therapies in Castration-resistant Prostate Cancer. Current Cancer Drug Targets, 2018, 18, 869-876.	0.8	3
70	Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications. Current Cancer Drug Targets, 2018, 18, 967-978.	0.8	14
71	Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Annals of Oncology, 2017, 28, 1508-1516.	0.6	213
72	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. Prostate, 2017, 77, 1012-1019.	1.2	6

#	ARTICLE	IF	CITATIONS
73	Urinary RNA-based biomarkers for prostate cancer detection. <i>Clinica Chimica Acta</i> , 2017, 473, 96-105.	0.5	39
74	Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 15541.	1.6	11
75	Serum and Plasma Copy Number Detection Using Real-time PCR. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	3
76	Immunotherapy for Prostate Cancer: Where We Are Headed. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2627.	1.8	47
77	Vitamin D status among long-term survivors of testicular cancer. <i>Oncotarget</i> , 2017, 8, 36780-36786.	0.8	14
78	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016, 7, 54564-54571.	0.8	116
79	CYP17A1 Polymorphisms and Clinical Outcome of Castration-Resistant Prostate Cancer Patients Treated with Abiraterone. <i>International Journal of Biological Markers</i> , 2016, 31, 264-269.	0.7	10
80	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0158952.	1.1	45
81	Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 331.	1.6	13
82	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , 2016, 7, 376.	1.6	127
83	Cell-free DNA as a diagnostic marker for cancer: current insights. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6549-6559.	1.0	104
84	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. <i>BioDrugs</i> , 2016, 30, 263-273.	2.2	22
85	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 255-263.	1.6	10
86	Androgen receptor signaling pathways as a target for breast cancer treatment. <i>Endocrine-Related Cancer</i> , 2016, 23, R485-R498.	1.6	78
87	Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1089-1096.	1.5	17
88	Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Eur Urol</i> 2016;70:724-31. <i>European Urology</i> , 2016, 70, e168-e169.	0.9	1
89	The potential use of urine cell free DNA as a marker for cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1283-1290.	1.5	39
90	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 426-431.	0.9	9

#	ARTICLE	IF	CITATIONS
91	Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 1-12.	1.6	5
92	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 48-55.	0.9	14
93	Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. <i>Oncotarget</i> , 2016, 7, 85641-85649.	0.8	22
94	Circulating <i>AR</i> copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 37839-37845.	0.8	69
95	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015, 115, 764-771.	1.3	17
96	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015, 75, 1329-1338.	1.2	24
97	PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 39-43.	0.9	62
98	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	0.9	73
99	¹⁸ F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1276-1283.	3.3	83
100	High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1377-1384.	0.7	80
101	Circulating cell-free <i>AR</i> and <i>CYP17A1</i> copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>British Journal of Cancer</i> , 2015, 112, 1717-1724.	2.9	112
102	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015, 7, 312re10.	5.8	366
103	Taxane-related nail toxicity. <i>Lancet Oncology</i> , The, 2015, 16, e310-e311.	5.1	8
104	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 2881-2891.	1.1	12
105	Conditional Survival of Patients Treated With First-Line Chemotherapy for Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 244-249.	0.9	10
106	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16059-e16059.	0.8	2
107	Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. <i>Prostate</i> , 2014, 74, 1691-1696.	1.2	52
108	Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. <i>Endocrine-Related Cancer</i> , 2014, 21, 487-493.	1.6	59

#	ARTICLE	IF	CITATIONS
109	Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. <i>Journal of Infection</i> , 2014, 68, 1-20.	1.7	69
110	Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 91-98.	1.0	11
111	Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 11-24.	2.0	71
112	The emerging role of anti-angiogenic therapy in ovarian cancer. <i>International Journal of Oncology</i> , 2014, 44, 1417-1424.	1.4	18
113	Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>Oncotarget</i> , 2014, 5, 12448-12458.	0.8	92
114	Circulating tumor cells: utopia or reality?. <i>Future Oncology</i> , 2013, 9, 1337-1352.	1.1	20
115	T cell receptor variable \hat{I}^2 gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. <i>Clinical and Experimental Immunology</i> , 2013, 172, 254-262.	1.1	8
116	Metabolic Syndrome as a Peculiar Target for Management of Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 211-220.	0.9	17
117	Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. <i>Lung Cancer</i> , 2013, 81, 328-336.	0.9	49
118	The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 42-51.	2.0	46
119	<i>H. pylori</i> infection and gastric cancer: State of the art. <i>International Journal of Oncology</i> , 2013, 42, 5-18.	1.4	178
120	B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia. <i>Hepatology</i> , 2013, 58, 448-448.	3.6	3
121	Precancerous colorectal lesions. <i>International Journal of Oncology</i> , 2013, 43, 973-984.	1.4	92
122	SAT0175â€¦Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A640.2-A641.	0.5	0
123	Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection. <i>Medicine (United States)</i> , 2013, 92, 245-256.	0.4	40
124	Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial. <i>Oncologist</i> , 2012, 17, 359-366.	1.9	142
125	In Reply. <i>Oncologist</i> , 2012, 17, e24-e25.	1.9	0
126	Hepatitis C Virus Infection and Mixed Cryoglobulinemia. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	61

#	ARTICLE	IF	CITATIONS
127	Barrett's esophagus and esophageal cancer: An overview. <i>International Journal of Oncology</i> , 2012, 41, 414-424.	1.4	58
128	Pegylated interferon- α , ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. <i>Blood</i> , 2010, 116, 343-353.	0.6	236
129	Role of the Receptor for the Globular Domain of C1q Protein in the Pathogenesis of Hepatitis C Virus-Related Cryoglobulin Vascular Damage. <i>Journal of Immunology</i> , 2009, 183, 6013-6020.	0.4	67
130	Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. <i>Blood</i> , 2008, 112, 1620-1627.	0.6	56